MY
MYO.US Myomo Inc
- Market cap
- USD 49.3M
- P/E
- -
- P/B
- 17.93x
- ROE
- -546.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MYO.US undervalued?
Graham numberThe Graham number of Myomo Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Myomo Inc fundamental analysis
No fundamental analysis for Myomo Inc yet.
Myomo Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Myomo Inc
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration softw…
Full company profileMyomo Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Myomo Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.10M | 1.56M | 2.44M | 3.84M | 7.58M | 13.9M | 15.6M | 19.2M | 32.6M | 40.9M | 45.5M |
| Gross Profit | 821K | 1.05M | 1.72M | 2.92M | 4.98M | 10.3M | 10.3M | 13.2M | 23.2M | 26.9M | 32.2M |
| Operating Income | -3.28M | -6.55M | -10.5M | -10.8M | -10.5M | -10.3M | -10.7M | -8.23M | -6.21M | -14.4M | -9.51M |
| EBITDA | -3.27M | -6.54M | -10.5M | -10.7M | -11.0M | -9.95M | -10.1M | -7.47M | -5.04M | -12.2M | -11.1M |
| Net Income | -3.62M | -12.1M | -10.3M | -10.7M | -11.6M | -10.4M | -10.7M | -8.15M | -6.18M | -15.6M | -15.0M |
| EPS | -0.56 | -84 | -25 | -19 | -3.47 | -1.78 | -1.52 | -0.28 | -0.16 | -0.37 | -0.34 |
| Balance Sheet | |||||||||||
| Total Assets | 1.66M | 14.0M | 8.28M | 6.60M | 14.7M | 20.1M | 10.2M | 14.6M | 42.2M | 38.6M | 33.8M |
| Total Liabilities | 19.2M | 1.53M | 1.86M | 4.77M | 3.14M | 4.69M | 3.80M | 5.59M | 17.5M | 27.2M | 31.1M |
| Shareholders' Equity | -17.5M | 12.4M | 6.43M | 1.82M | 11.6M | 15.4M | 6.36M | 8.99M | 24.7M | 11.4M | 2.75M |
| Cash & Short-term Investments | 797K | 13.0M | 6.54M | 4.47M | 12.2M | 15.5M | 5.35M | 8.87M | 24.9M | 18.4M | 11.9M |
| Total Debt | 5.45M | - | - | 2.65M | 173K | 735K | 554K | 601K | 8.11M | 19.4M | 21.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.20M | -6.15M | -9.61M | -10.3M | -9.03M | -9.55M | -10.2M | -6.17M | -3.29M | -14.5M | -7.26M |
| Capital Expenditure | 1.87K | 67.0K | 127K | 52.0K | 45.8K | 326K | 112K | 146K | 1.36M | 1.74M | 548K |
| Free Cash Flow | -3.20M | -6.22M | -9.73M | -10.4M | -9.08M | -9.87M | -10.3M | -6.32M | -4.65M | -16.3M | -7.81M |
| Ratios | |||||||||||
| ROE | - | -97.2% | -160.5% | -587.1% | -100.0% | -67.3% | -168.6% | -90.6% | -25.0% | -136.6% | -546.0% |
| ROA | -218.1% | -86.6% | -124.6% | -162.4% | -78.6% | -51.6% | -105.5% | -55.9% | -14.6% | -40.3% | -44.4% |
| Net Profit Margin | -327.8% | -776.0% | -422.1% | -279.1% | -152.5% | -74.9% | -68.9% | -42.3% | -19.0% | -38.1% | -33.0% |
| Debt to Equity | - | - | - | 1.45x | 0.01x | 0.05x | 0.09x | 0.07x | 0.33x | 1.70x | 7.78x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Myomo Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 1.86K | 0.00 | - |
| 2019 | USD 2.71M | 4.89 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:30 on Jan 31, 2020.
Who owns Myomo Inc
- Insiders 10.44%
- Institutions 35.76%
- Public & others 53.80%
- Shares outstanding 40.1M
- Free float 27.8M
Myomo Inc company profile
- Company name
- Myomo Inc
- Ticker
- MYO.US
- Exchange
- USA Stocks
- Listed since
- Jun 12, 2017
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 194
- Fiscal year end
- December
- Address
- 45 Blue Sky Dr., Burlington, MA, United States, 01803
- Phone
- 617 996 9058
- Website
- myomo.com
About Myomo Inc
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device; MyoGames, a virtual training platform; and MyoPro 2x Video Library. In addition, the company offers MyoCare, a post-delivery program that provides follow-up care with clients, therapists, and referral sources; MYOMO; MyoPal; and MyoCoach. Its products are designed to help adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, veteran's administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.
Myomo Inc management
9- Mr. Paul R. GudonisPresident, CEO & Chairman · born 1955
- Mr. David A. HenryChief Financial Officer · born 1961
- Dr. Harry Kovelman M.D.Chief Medical Officer · born 1959
- Mr. Colin AndersonSenior Director of Global Operations
- Ms. Galina ShtivelmanVice President of Human Resources
- Mr. Micah J. MitchellExecutive Officer · born 1976
- Ms. Mary-Katherine McClureChief Commercial Officer
- Ms. Amy Vetrano-PalmerSenior Director & Corporate Controller
- Ms. Kathy SawyersSr. Director of Clinical Outcomes